Literature DB >> 20686029

Chromosomal integration of adenoviral vector DNA in vivo.

Sam Laurel Stephen1, Eugenio Montini, Vijayshankar Ganesh Sivanandam, Muhseen Al-Dhalimy, Hans A Kestler, Milton Finegold, Markus Grompe, Stefan Kochanek.   

Abstract

So far there has been no report of any clinical or preclinical evidence for chromosomal vector integration following adenovirus (Ad) vector-mediated gene transfer in vivo. We used liver gene transfer with high-capacity Ad vectors in the FAH(Deltaexon5) mouse model to analyze homologous and heterologous recombination events between vector and chromosomal DNA. Intravenous injection of Ad vectors either expressing a fumarylacetoacetate hydrolase (FAH) cDNA or carrying part of the FAH genomic locus resulted in liver nodules of FAH-expressing hepatocytes, demonstrating chromosomal vector integration. Analysis of junctions between vector and chromosomal DNA following heterologous recombination indicated integration of the vector genome through its termini. Heterologous recombination occurred with a median frequency of 6.72 x 10(-5) per transduced hepatocyte, while homologous recombination occurred more rarely with a median frequency of 3.88 x 10(-7). This study has established quantitative and qualitative data on recombination of adenoviral vector DNA with genomic DNA in vivo, contributing to a risk-benefit assessment of the biosafety of Ad vector-mediated gene transfer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20686029      PMCID: PMC2937808          DOI: 10.1128/JVI.00751-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

Review 1.  Rates of spontaneous mutation.

Authors:  J W Drake; B Charlesworth; D Charlesworth; J F Crow
Journal:  Genetics       Date:  1998-04       Impact factor: 4.562

2.  Novel use of polymerase chain reaction to amplify cellular DNA adjacent to an integrated provirus.

Authors:  J Silver; V Keerikatte
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

3.  Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect.

Authors:  E A Kvittingen; H Rootwelt; P Brandtzaeg; A Bergan; R Berger
Journal:  J Clin Invest       Date:  1993-04       Impact factor: 14.808

4.  Increased cloning efficiency by temperature-cycle ligation.

Authors:  A H Lund; M Duch; F S Pedersen
Journal:  Nucleic Acids Res       Date:  1996-02-15       Impact factor: 16.971

5.  On the mechanism of recombination between adenoviral and cellular DNAs: the structure of junction sites.

Authors:  W Doerfler; R Gahlmann; S Stabel; R Deuring; U Lichtenberg; M Schulz; D Eick; R Leisten
Journal:  Curr Top Microbiol Immunol       Date:  1984       Impact factor: 4.291

6.  Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I.

Authors:  K Overturf; M al-Dhalimy; C N Ou; M Finegold; R Tanguay; A Lieber; M Kay; M Grompe
Journal:  Hum Gene Ther       Date:  1997-03-20       Impact factor: 5.695

7.  Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.

Authors:  K Overturf; M Al-Dhalimy; R Tanguay; M Brantly; C N Ou; M Finegold; M Grompe
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

8.  Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice.

Authors:  M Grompe; M al-Dhalimy; M Finegold; C N Ou; T Burlingame; N G Kennaway; P Soriano
Journal:  Genes Dev       Date:  1993-12       Impact factor: 11.361

9.  Deletion of cellular DNA at site of viral DNA insertion in the adenovirus type 12-induced mouse tumor CBA-12-1-T.

Authors:  M Schulz; W Doerfler
Journal:  Nucleic Acids Res       Date:  1984-06-25       Impact factor: 16.971

Review 10.  Tyrosine and its catabolites: from disease to cancer.

Authors:  R M Tanguay; R Jorquera; J Poudrier; M St-Louis
Journal:  Acta Biochim Pol       Date:  1996       Impact factor: 2.149

View more
  34 in total

Review 1.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

Review 2.  Helper-dependent adenoviral vectors for liver-directed gene therapy.

Authors:  Nicola Brunetti-Pierri; Philip Ng
Journal:  Hum Mol Genet       Date:  2011-04-05       Impact factor: 6.150

3.  A Hybrid Adenoviral Vector System Achieves Efficient Long-Term Gene Expression in the Liver via piggyBac Transposition.

Authors:  Ryan P Smith; Jesse D Riordan; Charlotte R Feddersen; Adam J Dupuy
Journal:  Hum Gene Ther       Date:  2015-06       Impact factor: 5.695

4.  Vector sequences are not detected in tumor tissue from research subjects with ornithine transcarbamylase deficiency who previously received adenovirus gene transfer.

Authors:  Li Zhong; Shaoyong Li; Mengxin Li; Jun Xie; Yu Zhang; Brendan Lee; Mark L Batshaw; James M Wilson; Guangping Gao
Journal:  Hum Gene Ther       Date:  2013-09       Impact factor: 5.695

Review 5.  CRISPR/Cas9: at the cutting edge of hepatology.

Authors:  Francis P Pankowicz; Kelsey E Jarrett; William R Lagor; Karl-Dimiter Bissig
Journal:  Gut       Date:  2017-05-09       Impact factor: 23.059

6.  Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.

Authors:  Calvin J Stephens; Elvin J Lauron; Elena Kashentseva; Zhi Hong Lu; Wayne M Yokoyama; David T Curiel
Journal:  J Control Release       Date:  2019-02-13       Impact factor: 9.776

7.  Balloon catheter delivery of helper-dependent adenoviral vector results in sustained, therapeutic hFIX expression in rhesus macaques.

Authors:  Nicola Brunetti-Pierri; Aimee Liou; Priti Patel; Donna Palmer; Nathan Grove; Milton Finegold; Pasquale Piccolo; Elizabeth Donnachie; Karen Rice; Arthur Beaudet; Charles Mullins; Philip Ng
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

Review 8.  Experimental methods to preserve male fertility and treat male factor infertility.

Authors:  Kathrin Gassei; Kyle E Orwig
Journal:  Fertil Steril       Date:  2015-12-30       Impact factor: 7.329

Review 9.  Circumventing antivector immunity: potential use of nonhuman adenoviral vectors.

Authors:  Estrella Lopez-Gordo; Iva I Podgorski; Nicholas Downes; Ramon Alemany
Journal:  Hum Gene Ther       Date:  2014-03-25       Impact factor: 5.695

10.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.